Vaxxinity ub-312 parkinson's trial results published in nature medicine

Ub-312 is the first parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living.

VAXX Ratings Summary

VAXX Quant Ranking